CL2018002677A1 - Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. - Google Patents
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.Info
- Publication number
- CL2018002677A1 CL2018002677A1 CL2018002677A CL2018002677A CL2018002677A1 CL 2018002677 A1 CL2018002677 A1 CL 2018002677A1 CL 2018002677 A CL2018002677 A CL 2018002677A CL 2018002677 A CL2018002677 A CL 2018002677A CL 2018002677 A1 CL2018002677 A1 CL 2018002677A1
- Authority
- CL
- Chile
- Prior art keywords
- vildagliptin
- rosiglitazone
- metformin
- development
- treatment
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title abstract 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title abstract 3
- 208000031773 Insulin resistance syndrome Diseases 0.000 title abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960004586 rosiglitazone Drugs 0.000 title abstract 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 229960001254 vildagliptin Drugs 0.000 title abstract 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 title abstract 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 title 1
- 229960002397 linagliptin Drugs 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
- 229960005095 pioglitazone Drugs 0.000 title 1
- 229960004034 sitagliptin Drugs 0.000 title 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A) 500 A 1000MG METFORMINA, B) 0,5 A 0,9MG ROSIGLITAZONA O 5 A 10 MG PIOGLITAZONA, C) 10 A 40MG SITAGLIPTINA, 0,625 A 2MG LINAGLIPTINA O 10 A 40MG VILDAGLIPTINA, Y EXCIPIENTES; Y SU USO PARA EL TRATAMIENTO DEL DESARROLLO DE HIGADO GRASO NO ALCOHÓLICO, SINDROME DE INSULINO-RESISTENCIA Y LA DIABETES MELLITUS TIPO 2, SINDROME DE OVARIO POLIQUISTICOPHARMACEUTICAL COMPOSITION INCLUDING A) 500 TO 1000MG METFORMIN, B) 0.5 TO 0.9MG ROSIGLITAZONE OR 5 TO 10 MG PIOGLITAZONA, C) 10 TO 40MG SITAGLIPTINE, 0.625 TO 2MG LINAGLIPTINE OR 10 TO 40MG VILDAGLIPTIN, AND AND ITS USE FOR THE TREATMENT OF THE DEVELOPMENT OF NON-ALCOHOLIC FAT LIVER, INSULIN-RESISTANCE SYNDROME AND MELLITUS TYPE 2 DIABETES, POLYCHISTIC OVARY SYNDROME
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2018002677A CL2018002677A1 (en) | 2018-09-21 | 2018-09-21 | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2018002677A CL2018002677A1 (en) | 2018-09-21 | 2018-09-21 | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002677A1 true CL2018002677A1 (en) | 2019-02-01 |
Family
ID=65588808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002677A CL2018002677A1 (en) | 2018-09-21 | 2018-09-21 | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2018002677A1 (en) |
-
2018
- 2018-09-21 CL CL2018002677A patent/CL2018002677A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001340A1 (en) | Composed of pegylated insulin lispro or a salt thereof comprising a chain a of sec no: 1, a chain b of sec no: 3 and the peg is of a weight between 20 to 40 kda; use of said compound to treat hypoglycemia or diabetes; pharmaceutical composition comprising said compound; and process for making said compound. | |
| MX389091B (en) | TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. | |
| CL2008001821A1 (en) | Imidazo [2,1-b] -thiazole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of diabetes, metabolic syndrome, insulin resistance, among others. | |
| UY37998A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| CY1119582T1 (en) | HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine | |
| AR081254A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AVE0010 AND INSULIN GLARGINE | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| FI3229828T3 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| CY1114703T1 (en) | PHARMACEUTICAL COMPOSITION OF INCLUSIVE (1S) -1,5-ANHYRO-1- [5- (4-Ethoxybenzyl) -2-Methoxy-4-Methylphenyl] -1-Sulfuryl | |
| MX386413B (en) | THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND AN ERK INHIBITOR. | |
| PE20211069A1 (en) | COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE | |
| CL2006003672A1 (en) | COMPOUNDS DERIVED FROM PIRIMIDO- [4,5-B] -OXAZINAS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES AND / OR OBESITY. | |
| CR11418A (en) | TRANS-CLOMPHENE FOR METABOLIC SYNDROME | |
| CL2017001843A1 (en) | Lixisenatide and / or a pharmaceutically acceptable salt thereof for the treatment of pediatric patients with type 2 diabetes mellitus. | |
| CL2021002107A1 (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria. | |
| CO2022004572A2 (en) | Treatment of type 2 diabetes mellitus | |
| AR099299A1 (en) | INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| CL2007000485A1 (en) | ALISQUERENO SALT; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SALT; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES THAT CAN BE MODULATED BY THE INHIBITION OF THE RHENINE. | |
| MX2018013729A (en) | New dapagliflozin crystal form and preparation method and use thereof. | |
| CL2018002677A1 (en) | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. | |
| AR102978A1 (en) | FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA | |
| CO2020001514A2 (en) | Pharmaceutical composition for the prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan and rosuvastatin, and compound preparation including the same | |
| AR104947A1 (en) | COMPOSITION OF MULTIPLE PEPTIDES | |
| RU2018147275A (en) | A method for the treatment of type 2 diabetes in patients with steatohepatitis | |
| UY27766A1 (en) | COMBINATION OF INSULIN AND A THIAZOLIDINDIONA DERIVATIVE AND USE OF THE SAME TO TREAT DIABETES |